Position in ABCL
as of Jun 30, 2026
· filed Jul 17, 2026
Position Value
$146,449
+$79,075 QoQ
Shares Held
18,656
-3.4% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#100
of 150 holders
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ABCL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Ballentine Partners, LLC holds $12,066,429 across 29 Biotechnology names. ABCL ranks #27 (1.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
5,245 | $2,605,347 | |
| 2 | KRYS |
Krystal Biotech, Inc.
|
2,138 | $794,629 | |
| 3 | ARGX |
Argenx SE
|
772 | $716,237 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,054 | $657,210 | |
| 5 | INCY |
Incyte Corp
|
4,816 | $545,940 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,695 | $510,244 | |
| 7 | RPRX |
Royalty Pharma plc
|
9,027 | $506,143 | |
| 8 | HALO |
Halozyme Therapeutics, Inc.
|
6,331 | $495,526 |
All Filings in ABCL
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $146,449 | 18,656 | Shares | Other | 2026-07-17 | |
| 2026-03-31 | $67,374 | 19,305 | Shares | Other | 2026-05-14 | |
| 2025-12-31 | $63,622 | 18,603 | Shares | Other | 2026-02-03 | |
| 2025-09-30 | $125,805 | 25,011 | Shares | Other | 2025-11-03 | |
| 2025-06-30 | $81,253 | 23,689 | Shares | Other | 2025-07-15 | |
| 2024-12-31 | $58,430 | 19,942 | Shares | Other | 2025-01-16 | |
| 2024-09-30 | $53,903 | 20,732 | Shares | Other | 2024-10-23 | |
| No filing history on record for this holder in this stock. | ||||||